Table 3.
Disease severity and COVID-19 therapies used in 24 pregnant patients hospitalized for COVID-19 concern
| Characteristic | Hospitalized owing to COVID-19 concern (n=24)a |
|
|---|---|---|
| n | n (%) or median (IQR) | |
| Gestational age at admission (wk)b | 23 | 32.4 (26–36.1) |
| Admitted for COVID-19 concern and delivery indication | 24 | 3 (12.5) |
| Delivered while admitted for COVID-19 concernc | 22 | 9 (40.9) |
| Admitted to ICU | 24 | 8 (33.3) |
| Highest level of oxygen support | 24 | |
| None | 5 (20.8) | |
| Nasal cannula | 8 (33.3) | |
| High-flow nasal cannula | 3 (12.5) | |
| Nonrebreather mask | 4 (16.7) | |
| Mechanical ventilation | 4 (16.7) | |
| COVID-19 therapiesd | 24 | |
| None | 7 (29.1) | |
| Remdesivir | 9 (37.5) | |
| Hydroxychloroquine | 2 (8.3) | |
| Convalescent plasma | 2 (8.3) | |
| Dexamethasone | 3 (12.5) | |
| Vasopressor support | 24 | 4 (16.7) |
| Laboratory measurese | n (%) or median (range) | |
| Lowest white blood cell count (103 per μL blood) | 23 | 6.1 (2.8–19) |
| Lymphopenia (≤5.6×103 per μL blood) | 23 | 10 (43.5) |
| Highest aspartate aminotransferase (units/L) | 22 | 46 (12–377) |
| Elevated AST (≥33 units/L) | 22 | 17 (77.3) |
| Highest D-dimer (μg/mL) | 17 | 1.5 (0.2–4.5) |
| Elevated D-dimer (>3.3 μg/L) | 17 | 5 (29.4) |
| Highest C-reactive protein (mg/L) | 15 | 25.7 (1.6–281.1) |
| Elevated C-reactive protein (≥22.3 mg/L) | 15 | 8 (53.3) |
| Highest creatinine (mg/dL) | 23 | 0.7 (0.4–1.2) |
| Elevated creatinine (>0.9 mg/dL) | 23 | 1 (4.4) |
COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Lokken et al. COVID-19 disease and mortality in pregnancy. Am J Obstet Gynecol 2021.
Number (percentage) or median (IQR). One patient was hospitalized twice several months apart; clinical details are reported for the first hospitalization only during acute COVID-19 infection. An additional patient diagnosed as having SARS-CoV-2 at delivery was subsequently readmitted for COVID-19 concern after delivery
n=23, excluding 1 patient who was admitted after delivery
n=22, excluding 1 patient who was admitted after delivery and 1 first-trimester maternal death
Patients receiving multiple targeted COVID-19 therapies are included in each relevant category
Laboratory values represented the highest or lowest detected during hospitalization; for some patients, this was after delivery. Thresholds for abnormal laboratory values were specific to pregnancy.21